Kane Biotech (CVE:KNE) Trading 16.7% Higher – Here’s What Happened

Kane Biotech Inc. (CVE:KNE)’s stock price traded up 16.7% during trading on Thursday . The company traded as high as C$0.04 and last traded at C$0.04. 249,090 shares traded hands during trading, an increase of 24% from the average session volume of 201,259 shares. The stock had previously closed at C$0.03.

Kane Biotech Trading Up 16.7%

The company has a current ratio of 0.68, a quick ratio of 0.39 and a debt-to-equity ratio of -308.66. The company has a market capitalization of C$6.36 million, a price-to-earnings ratio of -1.75 and a beta of 1.03. The company has a fifty day moving average of C$0.03 and a 200-day moving average of C$0.04.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.